Related Experiment Videos
[Radiofrequency ablation for hepatocellular carcinoma]
Masaru Inagaki1, Takahito Yagi, Hiroshi Sadamori
1Dept. of Gastroenterological Surgery, Transplant, and Surgical Oncology, Okayama University Graduate School of Medicine and Dentistry.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 18, 2002
Summary
Radiofrequency ablation (RFA) effectively treated hepatocellular carcinoma (HCC) in patients with liver cirrhosis. This multimodal therapy showed excellent results with no recurrences observed in the study group.
Area of Science:
- Hepatobiliary Medicine
- Interventional Oncology
- Radiofrequency Ablation Technology
Context:
- Hepatocellular carcinoma (HCC) poses a significant global health challenge, often associated with underlying liver cirrhosis.
- Treatment options for HCC require effective and minimally invasive approaches to improve patient outcomes.
- Radiofrequency ablation (RFA) has emerged as a promising therapeutic modality for liver tumors.
Purpose:
- To evaluate the efficacy and safety of radiofrequency ablation (RFA) as a primary or recurrent treatment for hepatocellular carcinoma (HCC).
- To assess the role of RFA in combination with other therapies, such as transcatheter arterial embolization (TAE), in managing HCC.
- To determine the feasibility of RFA under various anesthesia and guidance methods (CT, US, laparotomy, transthoracic).
Summary:
- This study involved 14 patients with HCC and liver cirrhosis treated with RFA between May 2001 and March 2002.
- RFA was applied to solitary or multiple lesions, primary or recurrent tumors, with or without simultaneous TAE.
- Excellent ablation was achieved in all cases, with no additional therapy needed and no recurrences reported.
- The procedure involved a mean of 3.2 sessions per patient, with varying anesthesia and guidance techniques employed.
Impact:
- Radiofrequency ablation (RFA) demonstrates excellent therapeutic effects for hepatocellular carcinoma (HCC) when used as part of a multimodal treatment strategy.
- The findings support RFA as a viable and effective option for managing HCC, even in complex cases involving liver cirrhosis.
- This study highlights the potential for RFA to achieve complete tumor ablation and prevent recurrence, contributing to improved long-term patient survival.